Table 4 Treatment at hospital discharge.

From: Low platelet count at admission has an adverse impact on outcome in patients with acute coronary syndromes: from the START Antiplatelet registry

 

Normal count (1707, 90.1%)

Platelet < 150 > 100 k/µl (157, 8.3%)

Platelets < 100 k/µl (30, 1.6%)

Treatment at discharge

DAPT (n,% of the total population)

1581 (92.6%)

*134 (85.3%)

27 (90.0%)

 ASA-CLOP (n,%)

464 (29.3%)

*52 (38.8%)

*19 (70.3%)

 ASA-PRAS (n,%)

178 (11.2%)

13 (9.7%)

1 (3.7%)

 ASA-TICA (n,%)

939 (59.4%)

69 (51.5%)

7 (25.9%)

SAPT (N,%)

113 (6.6%)

23 (14.6%)

3 (10.0%)

OAC (overall) (n,%)

133 (7.8%)

*22 (14.2%)

6 (20.0%)

 OAC (n,%)

2 (1.5%)

2 (9.1%)

0 (0%)

 OAC + SAPT (n,%)

24 (18.0%)

6 (27.3%)

0 (0%)

 OAC + DAPT (n,%)

107 (80.4%)

14 (63.6%)

6 (20.0%)

Statins (n,%)

1640 (96.1%)

154 (98.1%)

28 (93.3%)

ACE-I/ARB (n,%)

1140 (66.8%)

100 (63.7%)

12 (40.0%)

Beta block (n,%)

1211 (70.9%)

109 (72.7%)

18 (60%)

CA (n,%)

70 (8.2%)

7 (4.5%)

0 (0%)

Nitrates (n,%)

138 (8.1%)

26 (16.5%)

2 (6.7%)

Diuretics (n,%)

431 (25.2%)

50 (31.8%)

14 (46.7%)

PPI (n,%)

1648 (96.5%)

154 (98.1%)

27 (90.0%)

  1. ACE-I/ARB ACE inhibitors/angiotensin receptor blockers, ASA-CLOP aspirin plus clopidogrel, ASA-PRAS aspirin plus prasugrel, ASA-TICA aspirin plus ticagrelor, BETA BLOCK beta blockers, CA calcium antagonists, DAPT dual antiplatelet therapy, OAC oral anticoagulants, PPI proton pump inhibitors, SAPT single antiplatelet therapy.
  2. *p < 0.05 vs normal platelet count (≥ 150 k/µl).